




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷: A61N 1/368, 1/39, 1/05	A2	(11) International Publication Number: WO 00/04950 (43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: PCT/US99/16656 (22) International Filing Date: 23 July 1999 (23.07.99) (30) Priority Data: 6,379,427 601/4 09/121,523 23 July 1998 (23.07.98) US (71) Applicant: INTERMEDICS INC. [US/US]; 4000 Technology Drive, Angleton, TX 77515 (US). (71)(72) Applicants and Inventors: ALT, Eckhard [DE/DE]; Eichendorff Strasse 52, D-85521 Ottobrunn (DE). SANDERS, Richard [US/US]; 14122 Lofty Mountain Trail, Houston, TX 77062 (US). STOTTS, Lawrence, J. [US/US]; 327 Linden Lane, Lake Jackson, TX 77566 (US). (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD AND APPARATUS FOR DUAL CHAMBER BI-VENTRICULAR PACING AND DEFIBRILLATION

**(57) Abstract**

Device and method are disclosed in which leads with pacing and defibrillating electrodes are implanted into both the right and left ventricles of a patient's heart to enable simultaneous pacing of both ventricles to reduce the width of the QRS complex of the patient's cardiac activity to a more normal duration, and, when appropriate, to apply electrical shock waveforms to both ventricles simultaneously for lower energy defibrillation of the ventricles. In applying the defibrillation therapy, the defibrillating electrode in the left ventricle may be used as the anode and the defibrillating electrode in the right ventricle may be used as the cathode, or both ventricular defibrillating electrodes may be the anode and the metal case in which the shock waveform generator is implanted may be the cathode. Implanting a lead with pacing and defibrillating electrodes in the right atrium enables selective pacing and defibrillation of the atria, in which atrial fibrillation is treated by applying the shock waveform across the right atrial and left ventricular defibrillation electrodes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND APPARATUS FOR DUAL CHAMBER BI-VENTRICULAR PACING AND DEFIBRILLATION

5

Background of the Invention

The present invention relates generally to implantable medical devices for treating cardiac dysrhythmias, and more particularly to a multi-mode device
10 which is adapted to provide bi-ventricular therapy to the patient's heart in response to sensing applicable dysrhythmias.

Progress in medicine is based largely on progress in the technology of devices and apparatus for administering therapy. For example, significant advances in design techniques that have resulting in continuing reductions in the
15 size of implantable defibrillators, including size of the function generator itself as well as in the heart leads associated therewith, have led to a capability to implant defibrillators at considerably lower risk to patients. During the first few years following the advent of implantable defibrillators, implant procedures required general anesthesia and thoracotomy, and the patient was faced with all
20 of the risks associated with opening the chest cavity. The morality rate of the procedure tended to limit widespread use of the device.

In recent years, with lower defibrillation thresholds (DFTs) and reduction in high voltage capacitor and battery sizes, smaller and more easily implantable devices have been developed, which have allowed this operation to be performed
25 today under only local anesthesia. Smaller diameter and more easily inserted transvenous lead systems have overcome the need for a thoracotomy, and mortality associated with the procedure has been concomitantly reduced to less than one percent. The cosmetic aspects of such an implantation have also improved, with device size and weight allowing it to be implanted in the pectoral
30 region that had previously been reserved for devices capable of only pacing functions, rather than the lower abdomen.

Nevertheless, at least two issues remain to be resolved with respect to present-day implantable defibrillators. For one thing, despite size reduction owing to the aforementioned advances in technology, the devices are still
35 relatively large. At present, the limitations on size reduction are primarily attributable to the magnitude of energy required to achieve successful

defibrillation with an adequate safety margin. A capacity for energy delivery of 25 to 32 joules (J), on average, currently remains the standard for implantable defibrillators. This minimum energy requirement mandates production and use of devices ranging from 40 to 50 cubic centimeters (cc) in volume and 80 to 100 grams (g) in weight.

Another issue that remains to be resolved is the provision of a continuously uniform, homogeneous electric field distribution during application of the relatively high energy defibrillating shocks to the heart. Studies performed on animals and humans indicate that to achieve a successful defibrillation with a lowered energy content shock requires a substantially uniform electric field distribution throughout the portion of the mass of cardiac tissue involved in the fibrillation. Lower energy requirement and fewer shocks to achieve a successful defibrillation are important not only from the standpoints of further size reduction and maintenance of an adequate reserve to increase the interval between defibrillator replacements, but also to avoid potential damage to the heart and skeletal frame of the patient that can occur with frequent or repeated application of high energy shocks.

Under typical defibrillator implant conditions, a coil is introduced into the right ventricle to serve as one electrode or pole, and the defibrillator case (or "can," as it is often called in the art) that houses the batteries, capacitors, electronic components and circuitry is used as the second pole for the current path during the defibrillation shock. As noted above, the defibrillator case can now be implanted in the pectoral region, usually on the left side, to provide a more effective defibrillation pathway. This is desirable from the standpoint of the implant technique and the cosmetic aspect, but produces an energy and electric field distribution that is not equal, uniform or homogeneous throughout the region of the heart involved in the fibrillation. Measurements performed by the applicants have demonstrated that during application of a shock waveform using standard case, lead and defibrillation coil placements, a field of significantly lower energy (in volts (v) per centimeter (cm), i.e., v/cm) is present at the apex of the left ventricle compared to certain other regions of the heart such as the right ventricular outflow tract. The average electric field strength in the latter region is five to eight times greater than at the apex of the left ventricle.

In practice, then, because a relatively lower energy field is present at some regions that may be critical to defibrillation, the energy gradient sufficient to achieve successful defibrillation by application of the shock waveform mandates an adequate energy level in those regions and, by extension, a
5 considerably higher electric field density in the normally higher energy field locations as well. The result is a further skewing of the inequality or inhomogeneity of the electric field distribution in the strategically important regions.

In one of its aspects, the present invention provides improvements in lead
10 and electrode placements to assist in developing an equal, homogeneous field distribution during application of a defibrillation shock to the heart.

Another problem encountered with present day defibrillators, however, is that despite their capability to provide adequate therapy for sudden electrical instabilities of the cardiac function, they are not similarly capable of providing
15 therapy for an underlying hemodynamically-compromised ventricular function. This means that the patient may suffer an ongoing deficiency in cardiac output, for example, even though the device is effective in correcting isolated events of fibrillation or pacing dysrhythmias.

Clinical investigation performed on patients who suffer from heart failure
20 (i.e., inability of the heart to pump the required amount of blood) indicates that for a certain subset of these patients simultaneous stimulation of the left and right ventricles may be advantageous. In the cardiac cycle, a P wave of the subject's electrocardiogram (ECG) is produced by a depolarization of the atrial fibers just before they contract, and, when the cardiac impulse reaches the
25 ventricular fibers to stimulate them into depolarization, a QRS complex is produced just before contraction of the ventricular walls. This is followed by a T wave which is indicative of the electrical activity occurring upon repolarization of the ventricular fibers. Simultaneous stimulation of the left and right ventricle would be beneficial therapy to patients whose ECG displays a marked
30 desynchronization in contraction of the two ventricular chambers. In such cases, it is observed that after a right ventricular stimulation, considerable time may elapse for the cardiac impulse to travel from the apex of the right ventricle

through the septum and to the free wall of the left ventricle, with the septum contracting earlier than the latter.

Consequently, the mechanical forces of the ventricular contraction are less favorable for an effective hemodynamic output in such patients. The
5 duration or width of the QRS complex may increase because of an injury to the Purkinje fibers that inhabit and stimulate the ventricular septum and the lateral ventricular walls, and which could therefore increase the time for the impulse to spread throughout the ventricular walls. Patients who display a lack of ventricular synchronization primarily exhibit a wide QRS complex indicative of
10 a bundle branch block -- generally a left bundle branch block. Rather than the normal QRS complex width that ranges between 80 to 120 milliseconds (ms), the width of the QRS complex for these patients ranges between 140 to 200 ms.

It is a principal aim of the present invention to provide a method and apparatus for improved hemodynamic performance in patients with heart failure,
15 utilizing an implantable defibrillator of reduced size and increased efficacy which produces a substantially uniform, homogenous electric field upon application of a defibrillation shock to the heart.

Summary of the Invention

20 The present invention provides simultaneous pacing of the left and right ventricles of the patient's heart, and, unlike the prior art in which a pacing lead is inserted into the right ventricle only (through the right atrium and tricuspid valve), a separate pacing lead is also inserted into the left ventricle. Defibrillation coils provided on separate lead wires may be sheathed in
25 respective ones of the two pacing leads for insertion therewith. A defibrillation coil is introduced on a lead into the right ventricle and is seated so that a sensing and stimulating electrode at its distal end resides at the apex of that chamber. An atrial defibrillation coil is inserted on another lead into the right atrium to enable stimulation of the atrial chamber, as appropriate, with pacing pulses and for
30 application of defibrillation shocks. These right chamber (ventricular and atrial) leads enable cardiac pacing stimulation in VVI, VVI-R, DDD, DDD-R, AAI, AAI-R, and other modes, and permit application of defibrillation shocks between the respective coil and the active can or case of the device.

According to the invention, a second ventricular lead is placed in the left ventricle by needle puncture of the arteria subclavia (left subclavian artery) or the brachiocephalic artery, and advancement into the left ventricular chamber through the aortic valve. To avoid interference with the mechanical function of the aortic valve during retrograde passage of this lead into the left ventricle, or thereafter while in place, the lead should be of relatively smaller diameter than traditional ventricular leads (e.g., in a range of 6 to 7 French, or less). Also, its outer surface should be composed of electrically insulative material of very low thrombogenicity (e.g., high performance silicone or polyurethane). Local formation of a thrombus that could embolize and travel to the brain through the aortic valve is additionally avoided by use of platelet (thrombocyte) inhibitors (e.g., preferably ticlopidine, but alternatively or additionally aspirin, GPIIb/IIIa blockers or other inhibitors of the fibrinogen receptor), and by plasmatic coagulation inhibitors (e.g., heparin and hirudin). Such inhibitors are preferably administered for a duration of about one to three months following the surgical procedure. This time period should be adequate to allow a build-up of protective connective tissue around the electrode and also to prevent adhesion of the lead body in the vicinity of the aortic valve.

The left ventricular lead is otherwise of similar construction to the right ventricular lead, and enables pacing stimulation of the left ventricle simultaneously with pacing stimulation of the right ventricle, with resulting improvement in hemodynamics, in large measure by virtue of more organized contraction and avoidance of mitral regurgitation. It is also possible, albeit difficult, to place a lead with a pacing electrode in the left atrium. This is achievable, preferably, by inserting the lead into the left atrium by access from the adjacent distal coronary sinus, or, alternatively, by access through the arterial septum wall from the right atrium. This enables simultaneous pacing of the right and left ventricles according to the preset A-V delay, in a DDD mode, plus the capability for bi-ventricular defibrillation.

Most importantly, placement of a defibrillation coil on a lead in the left ventricle allows a considerable reduction of the energy requirement necessary to achieve a successful shock (i.e., termination of ventricular fibrillation, and return to sinus rhythm), with a threshold (DFT) that may be as low as only 2 to 3 joules

(J.). To that end, the defibrillation shocks may be applied solely between the two (i.e., right and left) ventricular coil electrodes, and by creating a substantially equal and homogeneous electric field distribution around them through the two ventricular chambers. Alternatively, if individual parameters of thorax geometry and the heart make it necessary or desirable, the shock waveform may be applied between both ventricular coils, operating as one pole, and the device case acting as the other pole. In this alternative configuration, defibrillation is achieved with a somewhat higher DFT than the other, but still considerably below the thresholds seen in the prior art.

Thus, the present invention permits defibrillators with maximum available energy output capability of only 15 joules or less to be implanted with reasonable assurance of successful defibrillation with quite adequate safety margin, even in relatively enlarged hearts. Such low energy requirement means that devices weighing considerably less than 50 grams (g.) and having volumes of less than even 30 cubic centimeters (cc.) can be implemented for this purpose, so that the function generator portion of the device can be sized on the same order as devices that functioned solely as the DDD pacemaker of recent vintage. Hemodynamic improvement attained by simultaneously pacing the left and right ventricles also reduces the occurrence of fibrillation, and thus, the need for defibrillation.

In one aspect of the invention, an implantable medical interventional device is adapted to provide therapy to a patient in whom the device is implanted to treat cardiac dysrhythmias. The device includes function generating means for providing a plurality of functions corresponding to different levels of therapy for treatment of sensed dysrhythmias, including a pulse generator adapted for pacing the patient's heart by generating stimulating electrical pulses therefor. A pair of thin leads is coupled to the pulse generator and sized for insertion respectively into the left and right ventricles of the patient's heart when the device is implanted, for application of the stimulating electrical pulses thereto. Each of the leads includes an electrode located on the respective lead for positioning in stimulating relation to cardiac tissue in a respective one of the ventricles and, when energized together by the pulse generator, to simultaneously pace the left and right ventricles.

The lead adapted for insertion into the left ventricle includes an insulative sheath composed of a material of low thrombogenicity, such as a material selected from a group which includes high performance silicone and polyurethane. Also, the insulative sheath is coated at least in part with a biodegradable material to inhibit thrombus formation on the respective lead. The biodegradable material coating may be impregnated with at least one platelet inhibitor (preferably, iloprost) for timed release during disintegration of the coating. The coating may additionally or alternatively be impregnated with a plasmatic coagulation inhibitor such as heparin or hirudin for time release.

The function generator includes a shock generator adapted for defibrillating the patient's heart by generating higher voltage electrical shock waveforms. Each of the leads includes a defibrillation coil coupled to the shock generator and located on its lead to be positioned within a respective ventricle to apply an electrical shock waveform to establish a substantially homogeneous electric field of sufficient electrical energy through the ventricles for defibrillation thereof. The defibrillation coils constitute defibrillation poles, and when energized simultaneously the defibrillation coil in the left ventricle is the anode and the defibrillation coil in the right ventricle is the cathode. Alternatively, the ventricular defibrillation coils constitute a single defibrillation pole and are energized simultaneously as an anode, and the metal case within which the function generator is housed constitutes a second defibrillation pole which is energized together with the defibrillation coils as a cathode. An atrial pacing lead includes a pacing electrode coupled to the pulse generator, and a defibrillation coil adapted to be positioned within the right atrium and coupled to the shock generator for defibrillation of the atria.

A variation of the invention is implemented in an implantable pacemaker that includes a pulse generator, a right ventricular pacing lead with an electrode coupled to the pulse generator for positioning in the right ventricle to deliver stimulating pacing pulses from the generator thereto, a left ventricular pacing lead with an electrode coupled to the pulse generator for positioning in the left ventricle to deliver stimulating pacing pulses from the generator thereto, and means for applying selected ones of the stimulating pacing pulses to the right and left ventricular pacing leads for stimulating the ventricles simultaneously.

The pacemaker also includes an atrial pacing lead with an electrode coupled to the pulse generator and positioned in the right atrium to deliver stimulating pacing pulses thereto, and means for applying selected ones of the stimulating pacing pulses to the atrial pacing lead, timed for stimulating the atria.

- 5 A variation of the invention is implemented in an implantable defibrillator, which includes a shock generator for generating electrical shock waveforms, a right ventricular lead with a defibrillation electrode coupled to the shock generator for positioning the right ventricle to deliver electrical shock waveforms thereto, a left ventricular lead with a defibrillation electrode coupled
- 10 to the shock generator for positioning in the left ventricle to deliver electrical shock waveforms thereto, and means for selectively applying electrical shock waveforms of predetermined energy content simultaneously to the right and left ventricular defibrillation electrodes to establish a substantially homogeneous electric field distribution in the ventricles for defibrillation thereof. A right atrial
- 15 lead of the defibrillator includes a defibrillation electrode coupled to the shock generator for positioning in the right atrium to deliver electrical shock waveforms thereto, and the selectively applying means applies the electrical shock waveforms between the right atrial defibrillation electrode and one of the right ventricular defibrillation electrode, the left ventricular defibrillation
- 20 electrode, and the metal case of the shock generator, for defibrillation of the atria.

- Also according to the invention, a device-implemented method of treating cardiac dysrhythmias is performed with an implantable medical interventional device adapted to deliver therapy to an implant patient. The
- 25 device possesses the capability to provide pacing therapy to the patient's heart, and the method includes the steps of sensing a need for ventricular pacing, and responding to the sensed need by delivering pacing pulses simultaneously to both ventricles of the patient's heart. The device implemented method also includes the steps of sensing ventricular fibrillation, and responding to the
- 30 sensed ventricular fibrillation by delivering an electrical shock waveform simultaneously to both ventricles to establish an electric field of relatively uniform distribution and sufficient electrical energy through the ventricles for defibrillation thereof.

Another aspect of the invention resides in a method for providing therapy to a patient from a medical interventional device to treat cardiac dysrhythmias, wherein the device performs a plurality of functions corresponding to different levels of therapy for treatment of sensed dysrhythmias. The device responds to
5 each different type of sensed dysrhythmia to generate an electrical waveform therapy among a variety of therapies appropriate to terminate the respective sensed dysrhythmia, including at least electrical pulse and shock waveform therapies therefor. The method includes implanting an electrical lead with an electrode to deliver at least one of the pulse and shock waveform therapies in
10 each of the right and left ventricles, and electrically connecting each lead to the device to enable its electrode to receive at least one of the therapies.

In the method, prior to implanting the lead, at least a portion of the lead to be implanted in the left ventricle is coated with a biodegradable carrier impregnated with a thrombus inhibitor adapted to be time-released into blood in
15 the locality of the portion of the lead in the left ventricle during disintegration of the carrier, to avoid embolization of a thrombus thereat. The method includes selecting the biodegradable carrier to degrade harmlessly in the blood with negligible systemic impact, and selecting at least one of ticlopidine and aspirin as concomitant oral therapy and intravenous or subcutaneous administration of
20 heparin and hirudin, as the thrombus inhibitor. Also, at least one physical parameter of the biodegradable carrier is selected to fix complete disintegration of the carrier within a period of from about one month to about three months from the time of implanting the lead, for time-release of the thrombus inhibitor over the period. The electrical lead is placed in the left ventricle by puncturing
25 one of the subclavian and brachiocephalic arteries, inserting the lead through the puncture, and advancing the lead through the aortic valve into the left ventricle until the electrode is properly located therein. Each ventricular lead includes both a pacing electrode at the distal end of the lead and defibrillating electrode proximal of the pacing electrode, and advancement of each lead into the
30 respective ventricle includes placing the pacing electrode in proximity to excitable cardiac tissue of the ventricle.

In the method, the right and left ventricles are paced simultaneously, whereby to reduce the duration of the QRS complex of the patient's

electrocardiogram. Shocks are applied to the defibrillating electrodes of both the right and left ventricular leads simultaneously, whereby to improve uniformity of the electric field distribution through the ventricles to terminate ventricular fibrillation. And shocks are applied to the defibrillating electrodes of both the right atrial lead and the left ventricular lead simultaneously to terminate atrial fibrillation. Also, the local ECG is detected at the left and right ventricles, and the size, morphology and other characteristics thereof are compared to discriminate the origin of the tachycardia, such as to distinguish ventricular and supraventricular tachycardias from one another.

10

Brief Description of the Drawings

The above and still further aims, objects, aspects, features and attendant advantages of the present invention will become apparent from a consideration of the following detailed description of the presently contemplated best mode of practicing the invention, by reference to a preferred embodiment and method, taken in conjunction with the accompanying drawings, in which:

FIG. 1 is a block diagram of an embodiment of an implantable medical interventional device in which the present invention is used;

FIG. 2 is a perspective view of an exemplary header of the implantable medical interventional device of FIG. 1;

FIG. 3 is a partial front view of a patient, shown in phantom, illustrating some of the internal organs including the heart and related vascular system to show the relative locations of the implanted device and its related electrical leads as inserted into the heart; and

FIG. 4 is a simplified anterior view of the human heart showing the placement of the various leads and associated electrodes in the associated vessels and chambers thereof.

Detailed Description of the Preferred Embodiment and Method of the Invention

FIG. 1 is a block diagram of an exemplary embodiment of an implantable medical interventional device 10 having capabilities of pacing, cardioversion and defibrillation, all of the components of which may be entirely conventional except as otherwise described herein, in which the present invention may be

used. Device 10 includes a function generator 16 for providing a plurality of functions corresponding to different levels of therapy for treatment of dysrhythmias. These may include generating relatively low energy pulse waveforms for pacing therapy including anti-bradycardia and anti-tachycardia
5 pacing, moderate energy shock waveforms for cardioversion therapy, and relatively higher energy shock waveforms for defibrillation therapy. An output circuit of function generator 16 supplies the designated therapy to a set of leads and electrodes for delivering it to designated chambers of the heart. The output circuit may include capacitors and high voltage switches for producing high
10 energy defibrillating shocks, and the electrodes may include the biocompatible metal housing (i.e., the case, or "can") 11 of device 10 as an active electrode, if desired for a particular type of therapy.

Function generator 16 performs its therapy-generating and delivery functions under the control of a microprocessor 15 containing arithmetic, logic,
15 and control circuitry in conjunction with peripheral circuits or subsystems such as memory 12, clock 14, etc., as a central processing unit (CPU) for the device. The microprocessor responds to instructions to perform high speed, real-time functions for controlling the operation of the function generator. The memory units may be written to and read from, by telemetry between device 10 and a
20 program console 23 through a wand 25 via antenna 13, and with related software, so that the microprocessor performs desired functions. These functions may then be varied by means of the programming console, or programmer 23, by the device manufacturer or the patient's attending physician.

Sensing means 18 within or outside the device housing 11 detects any of
25 various physiologic parameters indicative of the patient's cardiac functions and physical status, to sense dysrhythmias and initiate appropriate response mechanisms from the device. Sensed parameters may include the patient's electrogram (ECG), heart rate and/or rhythm, status of rest, exercise or activity of the patient (e.g., using an accelerometer 36 within the case 11, as here, or in
30 its own separate housing), etc., the latter enabling the device 10 to provide a rate adaptive response, as well as other dysrhythmia correction therapies. The sensing means also includes conventional sensors of physiological signals for detecting congestive heart failure, for example.

Sense amplifier circuitry 20 responds to analog input signals 22 from the sensors (sensing means) 18 for processing thereof. The processed signals are converted to digital format by an analog-to-digital (A/D) converter 26 and the digital output is applied to logic circuitry 27 which interacts with microprocessor 15 and memory 12 to execute programmed operating instructions. If the sensed signals are indicative of a dysrhythmia, the device generates the appropriate conventional pacing, cardioverting, or defibrillating electrical waveforms from blocks 33, 34 and 35, respectively, of function generator 16 under the control of the microprocessor in response to the specific type of dysrhythmia. When no immediate demand for therapy is being imposed, the microprocessor reverts to a "sleep" mode, to be awakened at any time a therapy requirement is indicated by the sense signals.

Pacing therapy modes may include combinations of single and dual chamber sensing, pacing, and electrical response functions for treating bradycardia and pathologic tachycardia, as well for providing rate-adaptive pacing using the accelerometer 36 as an activity/exercise sensor. Additionally, the device is preferably programmed with memory modes and diagnostics including acquisition of real-time ECG morphology from intracardiac and surface leads, and trends thereof over time, as well as activation of memory or Holter functions in conjunction with various events. For example, the device may be programmed to undergo mode switching from DDD to VVI-R pacing when the patient is experiencing episodes of atrial fibrillation. In that event, the device will switch from DDD to VVI pacing mode automatically when a pathologic atrial tachycardia is detected, and reverts from VVI to DDD operation automatically when physiologic atrial tachycardia is sensed, distinct from the pacing therapy modes selected by programming the device. The atrial ECG morphology, for example, is stored in the form of atrial signals detected prior to, during and after a cardiac dysrhythmia event, and this morphology is retrieved from the implanted device memory at a later time using telemetry and the external program console. This enables interpretation of cardiac activity that led up to the event of interest, the onset of the event, and the response of the patient's heart to the electrical waveform therapy subsequently delivered by the implanted device.

Some therapeutic output waveforms produced by the microprocessor-based function generator 16 may be used to treat more than one rhythm disorder. For example, a burst of pulses may be used for therapy to terminate a tachycardia, or may be one among a hierarchy of therapy responses selectively delivered to perform cardioversion. The waveform representing the appropriate therapy to treat the sensed dysrhythmia within the designed capabilities of device 10, i.e., pulses, pulse bursts or trains, low energy or high energy shocks, is applied through output circuitry 37 to the applicable heart lead(s) 40 for delivery to preselected locations within the heart. These and other leads may also convey sensed signals from electrodes in or on the heart or at other appropriate locations of the patient's body, and may acquire the ECG morphologies, for return to the device (e.g., for application to the sense amplifier, or for storage in memory and subsequent retrieval by the programming console via telemetry).

FIG. 2 shows the header 50 of case 11 which incorporates an electrical connector block 52 including receptacles (e.g., 54, 55, 56) for receiving the heart leads 40. The distal ends of the leads are inserted by the physician into the appropriate preselected locations within the patient's heart, and are then connected to the circuitry within the function generator of the device 10 by means of the plug connectors at the proximal ends of the leads, which are inserted into the proper receptacles. It should be emphasized that the connector portion of the header shown in FIG. 2 is not intended to represent a complete connector. As pointed out above, other leads may be plugged into appropriate receptacles for delivering sense signals from the heart or elsewhere in the body, including signals indicative of ECG morphology.

The receptacles 54, 55, 56 of the connector block 52 are sized or otherwise coded to avoid or prevent acceptance of the plug-in connector of any lead other than the proper lead for electrical connection to the internal circuitry of device 10. Once the leads are in place and connected to the device various tests are performed to assure that they are properly seated, such as to detect capture and suitable threshold. Various unique aspects of the connector portion of the device will be discussed in greater detail presently.

FIGS. 3 and 4 represent a phantom partial front view of a patient 60 illustrating the position of the device case 11 implanted in the left pectoral region

of the chest, and a more detailed anterior section view of the heart 61 showing the placement of the various heart leads and electrodes. Connected to the function generator 16 of device 10 via connector block 52 is an atrial lead 63 which has its bipolar electrode 64 positioned in close proximity to excitable
5 tissue in the right atrium 65 of the patient's heart 61, for sensing and pacing cardiac activity of the atrium. Right atrial lead 63 has a coil electrode 62 coupled by a separate wire in the sheath of the lead to defibrillator shock generator 35 when the lead is inserted into the proper receptacle of connector block 52.

10 A ventricular lead 66, with a distal electrode 67 positioned at the apex 69 of the right ventricle 68 when the lead is properly seated, is connected at its proximal end to the proper receptacle of connector block 52 of header 50 of case 11 and is used to sense and pace cardiac activity of the right ventricle. Ventricular lead 66 includes a coil electrode 70, which is on a separate electrical
15 wire, but encompassed in the same sheath as the wire connected to electrode 67, for positioning within the right ventricle when lead 66 is properly seated. Defibrillation shocks are applied to coil electrode 70 in the right ventricle 68 to establish an electric field relative to a counter-electrode outside the heart, which is typically the metal can or case 11 that houses the electronics and batteries of
20 device 10. The location of the case implanted in the left pectoral region of the patient's chest assures that the field will be present over a large part of the mass of the ventricular walls.

According to the present invention, separate pacing leads 72 and 66 are implanted in the left and right ventricles 75, 68, respectively, of the patient's
25 heart to allow the ventricles to be paced simultaneously. For purposes of ventricular defibrillation, each of these ventricular leads also has its own separate defibrillation coil (77, 70, respectively). the right ventricular lead 66 is introduced into the right ventricle in the usual manner by venous access, such as via the vena subclavia either by puncture or by a cutdown of the vena cephalica.
30 As noted above, this lead is placed with its distal electrode 67 resident at the apex 69 of the chamber, for electrical stimulation to pace the ventricle 68 and, in the event of ventricular fibrillation, to deliver a defibrillation shock to the

ventricle, by application of appropriate electrical signals to the proximal end of the lead via the connector block in the header of the implanted defibrillator.

The right atrial lead 63 provides pacing stimulation via electrode 64 to the right atrial chamber 65 from device 10, and also enables defibrillating shocks to be delivered to its associated coil electrode 62 in that chamber from the defibrillator section of the device to which the atrial lead is also connected at the header. These leads allow stimulation in VVI, VVI-R (by means of an activity sensor in the defibrillator), DDD, DDD-R, AAI, AAI-R, and other modes. The defibrillating shocks can be applied between the coil of the respective lead and the active can 11.

According to the invention, a left ventricular lead 72 is inserted into the left ventricle 73 by advancement into the arteria subclavia 74 which is either punctured or exposed by surgical preparation for access to the arterial system. Alternatively, the left ventricular lead may be implanted by puncture of the truncus brachiocephalicus and insertion through that puncture. Another technique is to surgically expose either the subclavian artery or the brachiocephalic artery and to apply a circular tightening suture ("tabakbeutelnaht"). This assists in tightening up the site of entry to avoid internal bleeding, which is especially important where subsequent anti-coagulation measures are employed by use of platelet inhibitors as is more fully explained below.

It is essential that the outer surface of this lead 72 be of very low thrombogenicity, such as by use of high performance silicone or polyurethane insulation, and by other techniques which will be described presently. It is also important that the lead body be of very small diameter, e.g., in a range from less than about 7 F, so as not to compromise the mechanical function of the aortic valve 80 during retrograde passage into the left ventricle 75 or during the valve's operation in the cardiac cycle.

Advanced materials and fabrication techniques have enabled reductions in size of heart lead diameters for implantable defibrillators to a range of 5 to 7 French (1.66 mm to 2.33 mm) from previous sizes that ranged from 9 to 11 French (i.e., 3.00 mm to 3.66 mm). More recent developments in coated wire techniques have made it possible to produce lead diameters in an even smaller

range, of from 4 to 6 French (1.33 mm to 2.00 mm). These small sizes make it much easier to insert the defibrillator leads through the vascular system to the heart, and to place the leads and associated electrodes or poles in the desired position(s) in the appropriate chamber(s) of the heart.

5 The left ventricular lead 72 has a pacing (and sensing) electrode 73 located at its distal end, which is seated at the apex 74 of left ventricle 75 when the lead is properly and fully inserted in place. This lead also has a defibrillation coil electrode 77. After insertion through the puncture opening in the left subclavian artery or the brachiocephalic artery, the lead 72 is inserted by
10 retrograde passage through the aortic valve 80 into the left ventricle 75, as shown more clearly in FIG. 4.

 The major concern in placement of a left ventricular lead lies in the potential generation of a thrombus on the defibrillator coil. A locally formed thrombus especially in that location might embolize into the brain and cause a
15 cerebral stroke, death or major disability. While previous lead materials of choice have been relatively thrombogenic, with standard isolating materials having exhibited several layers of thrombocytes and other thrombotic depositions, particularly at the defibrillator coil, newer surface materials such as iridium oxide coated wires and titanium nitrate coated materials, have
20 demonstrated extremely low thrombogenicity. Therefore, successful placement and maintenance of the left ventricular lead can be achieved with considerably less concern by use of a lead with low thrombogenicity insulation as mentioned above, and having a surface coating of titanium nitrate or iridium oxide, for example, on the electrical wire.

25 In addition, as mentioned above, a pacing lead may be inserted into the left atrium, either by needle puncture and access to the left atrium through the adjacent distal coronary sinus, which is preferred, or through the atrial septum wall from the right atrium. The purpose is to enable simultaneous pacing of the right and left atrial chambers, and, following an appropriate delay representing
30 the atrioventricular (A-V) delay interval, simultaneous pacing of the right and left ventricles by application of the pacing stimuli to the respective leads.

 The additional use of systemically applied heparin (in the peri-operative setting) and especially the use of orally administered ticlopidine as thrombocyte

inhibitors over a limited period of time (e.g., from one to three months following the operation) can serve to prevent the incidence of local thrombus formation until protective connective tissue builds up around the electrode. Animal and human studies have demonstrated that a very thin protective layer of connective
5 tissue can be formed in as little as three to six weeks. Monocytes, which are present in the blood, deposit on the surface and convert into fibroblast, which builds this connective tissue. It is essential that the process should take place for a sufficient period of buildup of the connective tissue to shield the foreign body and later leave it as a neutral foreign body, to prevent thrombus formation. This
10 may be assisted as well by application to the lead surface of inhibitors of plasmatic coagulation, such as heparin and hirudin, and by inhibitors of platelet aggregation, such as aspirin, membrane or surface receptor GP (glycoprotein) IIb/IIIa blockers (i.e., platelet inhibitors that act on the GP IIb/IIIa receptor), or other inhibitors of the fibrinogen binding receptor.

15 These inhibitors may be applied by incorporating them into a biodegradable carrier which is used to coat the surfaces of interest, as disclosed in co-pending U.S. patent application Serial No. 08/798,333 of E. Alt et al, the specification of which is incorporated by reference herein. According to that invention, the carrier itself is a substance or composition that undergoes
20 continuous degradation or disintegration within the body to self-cleanse the coated surface as well as to release thrombus inhibitors incorporated in the coating. The carrier degrades slowly through hydrolytic, enzymatic or other degenerative processes. Blood components including albumin, adhesive proteins, and thrombocytes are unable to adhere to the protected surface because
25 of the continuous cleansing action along the entire surface. Additionally, the added inhibitors undergo slow release with the controlled degradation of the carrier.

The coating carrier is a synthetic or naturally occurring biodegradable polymer such as aliphatic and hydroxy polymers of lactic acid, glycolic acid,
30 mixed polymers and blends, polyhydroxybutyrates and polyhydroxy-valerates and corresponding blends, or polydioxanon, modified starch, gelatine, modified cellulose, caprolactaine polymers, polyacrylic acid, polymethacrylic acid or derivatives thereof, which will not alter the structure or function of the material

to which it is superficially applied. The biodegradable polymer disintegrates with consequent slow release of the drugs (i.e., the inhibitors) incorporated therein, while in contact with blood or other body fluids.

The carrier layer (which is represented by reference number 90 in FIG. 4 for the sake of illustration, but which may be restricted to portions of the respective leads at and near the electrodes) is applied in an extremely thin and tightly adherent layer less than about 100 microns (μm) thick -- even a coating of only 10 μm -- to the surface of the lead. It is prepared as a liquid or semi-liquid phase of the selected carrier material, and applied in a very thin, paint-like layer or multiple layers by dipping or spraying, followed by drying of the carrier. Its disintegration over time may be carefully controlled, and the disintegration takes place without harm to the tissue, blood or other fluids of the body. The selected inhibitors are incorporated in the carrier coating for timed release therefrom as the carrier disintegrates, by virtue of the controlled time of disintegration of the carrier. The time of disintegration may be adjusted by varying the thickness of the carrier coating or of its multiple layer along with and/or as well as by factors such as the biodegradable carrier material(s) selected and the specific time release characteristics of the incorporated drugs. Applying the biodegradable coating in multiple, different layers (i.e., with different inhibitors/additives) of the same or different thickness can provide prolonged action of a particular inhibitor and enable different beneficial actions to occur at predetermined different intervals of time. For example, the innermost coating layer (relative to the lead and/or electrode surface) may be intended to provide the most prolonged action, while the outermost layer is intended primarily for near term response to its initial exposure to blood. After the biodegradable material has completely disintegrated, which may be set as a period of several weeks or months, thrombus formation continues to be inhibited because by the time the controlled period has elapsed the lead will have been coated by connective tissue.

Application of the carrier coating with added anti-inflammatory or anti-coagulant substances therein to the electrode(s) of the lead inhibits a build-up of scar tissue on the electrode at the electrode-myocardial (endocardial) tissue interface in the case of the pacing electrode, or the formation of thrombi in the case of the defibrillation electrode, or at the site of passage through the aortic

valve, to prevent adhesion of the lead to the leaflets of the valve. The amount and dosage of the drug(s) incorporated into and released from the biodegradable carrier may be prescribed to suppress the thrombus formation process locally without otherwise affecting normal systemic functions.

5 With both the left ventricular lead 72 and the right ventricular lead 66 in place, pacing stimulation from the implanted device 10 may be applied simultaneously to both pacing electrodes 73 and 67 of the respective ventricular chambers. By synchronizing the mechanical contraction from the apex of the heart, considerable improvement in hemodynamics can be achieved in many
10 patients. This is partly a result of a more organized contraction, and partly an avoidance of mitral regurgitation, which often additionally compromises the left ventricular function. Hemodynamic improvement has been shown to reduce the occurrence of fibrillation, and thus, the need for defibrillation, with concomitant savings of energy consumption and increased longevity of the implanted device.

15 Use of pacing electrodes in both the right and left ventricles avoids many problems associated with prior art left ventricle stimulation. And the retrograde ventricular access through the aorta and aortic valve 80 to the left ventricle 75 is achieved by a relatively simple procedure of puncturing the subclavia or the brachiocephalic artery which can be done under local anesthesia, in avoidance of
20 a need for and risks of major surgical measures.

 Moreover, placement of a defibrillation coil 77 in the left ventricle as well as a defibrillation coil 70 in the right ventricle allows defibrillation shocks to be delivered solely between these two electrodes, to considerably reduce the energy requirements of a successful shock. Even where individual parameters of
25 thorax geometry and of the heart within the thorax may necessitate use of the two ventricular coils as a single pole and of the defibrillator case as the other pole, a substantial reduction in the energy consumption needed for defibrillation is achieved. By virtue of creating a substantially equal electric field distribution around the two ventricular electrodes and through the ventricular chambers, it is
30 possible to implant a defibrillator having a maximum available energy output of only 15 joules to achieve successful defibrillation with adequate safety margin, even in patients with an enlarged heart. This means that the implanted device of the invention can be produced with a weight considerably less than 50 grams and

a volume of less than 30 cc, which compares favorably in weight and size with the DDD pacing-limited device types which were being implanted only a few years ago. Cosmetic advantages and reduction of patient discomfort are added advantages of the size and weight reductions.

- 5 Provision of a coil on the right atrial lead 63 enables treatment of atrial fibrillation, with a capability of four-way application of shocks between the defibrillation coil 62 in the right atrium 65 and defibrillation coil 77 in the left ventricle 75, or defibrillation coil 70 in the right ventricle 68, or the case 11, -- or of coil 62 against a combination of defibrillation coils 77 and 70 and case 11
10 together -- to create a relatively homogeneous electric field through the atria.

- Additionally, the lead 63 in the right atrium facilitates discrimination between supraventricular tachycardia (originating from outside the ventricle, generally either from the SA node or AV node or the atrium) and ventricular tachycardia. It provides a knowledge of the underlying atrial rhythm as well as
15 of the ventricular rhythm by detecting the local ECG simultaneously at the left and right ventricles and the right atrium, for comparison. If a complete dissociation between the ventricular arrhythmia and the atrial rhythm is found, the diagnosis of ventricular tachycardia would be virtually conclusive. In that case, an anti-tachycardia therapy may be delivered by the device and associated
20 lead(s) to the ventricle. However, if the discrimination algorithm determines the atrium to be the primary source of the present tachycardia, the therapeutic intervention would instead be generated and delivered as appropriate to treat a diagnosed primary atrial tachyarrhythmia.

- Although a presently contemplated best mode of practicing the invention
25 has been described herein, it will be recognized by those skilled in the art to which the invention pertains from a consideration of the foregoing description of a presently preferred embodiment, that variations and modifications of this exemplary embodiment and method may be made without departing from the true spirit and scope of the invention. Accordingly, it is intended that the
30 invention shall be limited only by the appended claims and the rules and principles of applicable law.

WHAT IS CLAIMED IS:

1. An implantable medical interventional device adapted to provide therapy to a patient in whom the device is implanted to treat cardiac
5 dysrhythmias, said device comprising function generating means for providing a plurality of functions corresponding to different levels of therapy for treatment of sensed dysrhythmias, including a pulse generator adapted for pacing the patient's heart by generating stimulating electrical pulses therefor; and a pair of thin leads coupled to said pulse generator and dimensioned for insertion respectively into
10 the left and right ventricles of the patient's heart when said device is implanted, for application of said stimulating electrical pulses thereto, each of said leads including an electrode located on the respective lead for positioning in stimulating relation to cardiac tissue in a respective one of said ventricles and, when energized in unison by said pulse generator, to simultaneously pace said
15 left and right ventricles.
2. The device of claim 1, wherein said lead adapted for insertion into the left ventricle includes an insulative sheath composed of a material of low thrombogenicity.
20
3. The device of claim 2, wherein said material of low thrombogenicity is selected from a group which includes silicone and polyurethane.
- 25 4. The device of claim 2, wherein said insulative sheath is coated at least in part with a biodegradable material to inhibit thrombus formation on the respective lead means.
5. The device of claim 4, wherein said biodegradable material
30 coating includes at least one platelet inhibitor incorporated therein for timed release during disintegration of said coating.

6. The device of claim 5, wherein said at least one platelet inhibitor is iloprost.

7. The device of claim 5, wherein said biodegradable material
5 coating further includes a plasmatic coagulation inhibitor incorporated therein for timed release during disintegration of said coating.

8. The device of claim 7, wherein said plasmatic coagulation inhibitor is selected from a group which includes heparin and hirudin.

10

9. The device of claim 1, wherein said function generator includes a shock generator adapted for defibrillating the patient's heart by generating higher voltage electrical shock waveforms therefor; and each of said pair of leads further includes a defibrillation coil coupled to said shock generator and located
15 on the respective lead so as to be positioned within a respective one of said ventricles and adapted, when energized by said shock generator, for applying an electrical shock waveform to establish a substantially homogeneous electric field of sufficient electrical energy through the ventricles for defibrillation thereof.

20 10. The device of claim 9, wherein the defibrillation coils on respective ones of said pair of leads constitute defibrillation poles, and are adapted to be energized simultaneously so that the defibrillation coil on the lead to be positioned in the left ventricle is the anode and the defibrillation coil on the lead to be positioned in the right ventricle is the cathode.

25

11. The device of claim 9, wherein said function generator is housed within a metal case, and the defibrillation coils on said pair of leads constitute a defibrillation pole adapted to be energized simultaneously to act as an anode, in conjunction with said case constituting a defibrillation pole adapted when
30 energized together with said defibrillation coils to act as a cathode.

12. The device of claim 9, further including an atrial pacing lead coupled to said pulse generator, said atrial pacing lead including a defibrillation

coil located thereon so as to be positioned within the right atrium of the patient's heart when said device and leads are implanted, said atrial pacing lead defibrillation coil being coupled to said shock generator for defibrillation of the atrial chambers.

5

13. An implantable pacemaker, comprising a pulse generator for generating stimulating pacing pulses, a right ventricular pacing lead including an electrode coupled to said pulse generator and adapted to be positioned in the right ventricle of a patient's heart for delivery of stimulating pacing pulses
10 thereto, a left ventricular pacing lead including an electrode coupled to said pulse generator and adapted to be positioned in the left ventricle of the patient's heart for delivery of stimulating pacing pulses thereto, and means for applying selected ones of said stimulating pacing pulses timed for stimulating the ventricles simultaneously to said right and left ventricular pacing leads.

15

14. The pacemaker of claim 13, further comprising an atrial pacing lead including an electrode coupled to said pulse generator and adapted to be positioned in the right atrium of the patient's heart for delivery of stimulating pacing pulses thereto, and means for applying to said atrial pacing lead selected
20 ones of said stimulating pacing pulses timed for stimulating the atria.

15. An implantable defibrillator, comprising a shock generator for generating electrical shock waveforms, a right ventricular lead including a defibrillation electrode coupled to said shock generator and adapted to be
25 positioned in the right ventricle of a patient's heart for delivery of electrical shock waveforms thereto, a left ventricular lead including a defibrillation electrode coupled to said shock generator and adapted to be positioned in the left ventricle of the patient's heart for delivery of electrical shock waveforms thereto, and means for selectively applying said electrical shock waveforms of
30 predetermined energy content simultaneously to said right and left ventricular defibrillation electrodes to establish a substantially homogeneous electric field distribution in the ventricles for defibrillation thereof.

16. The defibrillator of claim 15, wherein said selectively applying means is adapted to apply said electrical shock waveforms either between said right and left ventricular defibrillation electrodes as separate poles, or between said right and left ventricular defibrillation electrodes as one pole and a metal case of said shock generator as another pole, for defibrillation of the ventricles.

17. The defibrillator of claim 15, further comprising a right atrial lead including a defibrillation electrode coupled to said shock generator and adapted to be positioned in the right atrium of the patient's heart for delivery of electrical shock waveforms thereto, and wherein said selectively applying means is adapted to apply said electrical shock waveforms between said right atrial defibrillation electrode and one of said right ventricular defibrillation electrode, said left ventricular defibrillation electrode, and a metal case of said shock generator, for defibrillation of the atria.

15

18. The defibrillator of claim 15, further comprising a pacing pulse generator, separate pacing electrodes on each of said right and left ventricular leads respectively coupled to said pulse generator and adapted to be positioned respectively in the right and left ventricles of the patient's heart for selective delivery of stimulating pacing pulses simultaneously thereto, and an atrial pacing lead including an electrode coupled to said pulse generator and adapted to be positioned in the right atrium of the patient's heart for selective delivery of stimulating pacing pulses thereto.

19. A device-implemented method of treating cardiac dysrhythmias with an implantable medical interventional device adapted to deliver therapy to an implant patient, wherein the device possesses the capability to provide at least pacing therapy to the patient's heart, said method including the steps of:

- sensing a need for ventricular pacing; and
- responding to said sensed need for delivering pacing pulses simultaneously to both ventricles of the patient's heart.

20. The device-implemented method of claim 19, wherein said device has separate right and left ventricular leads coupled thereto adapted for delivering sense signals indicative of a need for ventricular pacing to said device, and a pulse generator for delivering electrical pacing pulses simultaneously to
5 said right and left ventricular leads.

21. The device-implemented method of claim 19, wherein said device possesses the capability to provide a plurality of functions corresponding to different therapies for treatment of dysrhythmias, and further including the steps
10 of:

sensing ventricular fibrillation; and
responding to said sensed ventricular fibrillation by delivering an electrical shock waveform simultaneously to both ventricles of the patient's heart to establish an electric field of relatively uniform distribution and sufficient
15 electrical energy through the ventricles for defibrillation thereof.

22. The device-implemented method of claim 21, wherein said device has separate right and left ventricular leads coupled thereto adapted for delivering sense signals indicative of ventricular fibrillation to said device, and a
20 shock generator for delivering electrical shock waveforms simultaneously to said right and left ventricular leads.

23. The device-implemented method of claim 20, wherein said device further has a right atrial lead coupled to said pulse generator adapted for
25 delivering sense signals indicative of a need for atrial pacing of the patient's heart to said device, and for receiving pacing pulses for atrial stimulation of the patient's heart in response to said atrial sense signals.

24. The device-implemented method of claim 21, further including
30 the steps of:
sensing atrial fibrillation; and
responding to said sensed atrial fibrillation by delivering an electrical shock waveform between the right atrium and selectively either of the right and

left ventricles of the patient's heart to establish an electric field of sufficient electrical energy through the atrium for defibrillation thereof.

25. The device-implemented method of claim 22, wherein said device
5 has separate right and left ventricular leads coupled thereto adapted for delivering sense signals indicative of ventricular fibrillation to said device, a right atrial lead coupled to said device adapted for delivering sense signals indicative of atrial fibrillation to said device, and a shock generator for delivering electrical shock waveforms to said right atrial lead and said right and left
10 ventricular leads as necessary for defibrillation.

26. An implantable medical interventional device adapted to provide therapy to a patient in whom the device is implanted to treat cardiac dysrhythmias, said device comprising means responsive to different types of
15 sensed dysrhythmia for providing a level of therapy appropriate respectively thereto, including electrical pulse and shock waveforms of sufficiently high energy content to pace and defibrillate respectively; and means for application of a therapy simultaneously to both ventricles of the patient's heart.

20 27. The device of claim 26, wherein said application means includes a right ventricular lead and a left ventricular lead each including a pacing electrode and a defibrillating electrode separately coupled to said therapy-providing means.

25 28. An implantable medical interventional device adapted to provide therapy to a patient in whom the device is implanted to treat cardiac dysrhythmias, said device comprising means for providing a plurality of functions corresponding to different levels of therapy for treatment of dysrhythmias; means for sensing different types of dysrhythmias; means
30 responsive to each different type of dysrhythmia sensed by said sensing means for enabling said function providing means to provide an electrical waveform therapy among a variety of therapies appropriate to terminate the respective sensed dysrhythmia including pulse, low energy and high energy shock

waveforms; and means adapted to deliver at least one of said therapies concurrently to both ventricles of the patient's heart.

29. A method for providing therapy to a patient from a medical
5 interventional device to treat cardiac dysrhythmias, wherein the device performs a plurality of functions corresponding to different levels of therapy for treatment of sensed dysrhythmias, and responds to each different type of sensed dysrhythmia to generate an electrical waveform therapy among a variety of therapies appropriate to terminate the respective sensed dysrhythmia including at
10 least electrical pulse and shock waveform therapies therefor, the method comprising the steps of implanting an electrical lead that includes an electrode for delivering at least one of said pulse and shock waveform therapies in each of the right and left ventricles of the patient's heart, and electrically connecting each lead to said device to enable said electrode thereof to receive said at least
15 one of the therapies.

30. The method of claim 29, including, prior to implanting the lead, the step of coating at least a portion of the electrical lead to be implanted in the left ventricle with a biodegradable carrier impregnated with a thrombus inhibitor
20 adapted to be time-released into blood in the locality of said portion of the lead in the left ventricle during disintegration of said carrier, to avoid embolization of a thrombus thereat.

31. The method of claim 30, including the step of selecting the
25 biodegradable carrier to degrade harmlessly in the blood with negligible systemic impact, and selecting the thrombus inhibitor from a group comprising ticlopidine, aspirin, heparin, and hirudin.

32. The method of claim 31, including the step of selecting at least
30 one physical parameter of the biodegradable carrier to fix complete disintegration thereof within a period of from about one month to about three months from the time of implanting the lead, for time-release of the thrombus inhibitor over said period.

33. The method of claim 29, wherein the step of implanting the electrical lead in the left ventricle includes puncturing one of the subclavian and brachiocephalic arteries, inserting the lead through the puncture, and advancing the lead through the aortic valve into the left ventricle until said electrode is properly located therein.

34. The method of claim 33, wherein each said ventricular lead includes both a pacing electrode at the distal end of the lead and a defibrillating electrode proximal of the pacing electrode, and the step of advancing the lead through the aortic valve into the left ventricles includes placing the pacing electrode in proximity to excitable cardiac tissue of the left ventricle.

35. The method of claim 34, including the step of applying pulse therapy to the pacing electrodes of both the right and left ventricular leads for pacing the ventricles simultaneously, whereby to reduce the duration of the QRS complex of the patient's electrocardiogram.

36. The method of claim 34, including the step of applying shock waveform therapy to the defibrillating electrodes of both the right and left ventricular leads simultaneously, whereby to improve uniformity of the electric field distribution through the ventricles to terminate ventricular fibrillation.

37. The method of claim 36, wherein the step of applying said shock waveform therapy to the defibrillating electrodes of both the right and left ventricular leads simultaneously includes applying said shock waveform therapy to the defibrillating electrode in the left ventricle as the anode and to the defibrillating electrode in the right ventricle as the cathode.

38. The method of claim 36, wherein said device is implanted in a pectoral region of the patient, and the step of applying said shock waveform therapy to the defibrillating electrodes of both the right and left ventricular leads simultaneously includes applying said shock waveform therapy to said defibrillating electrodes in the ventricles as the anode and to an electrically

conductive case in which the therapy-providing means of said device are housed as the cathode.

39. The method of claim 34, including the steps of implanting an
5 electrical lead with a pacing electrode and a defibrillating electrode thereon in the right atrium of the patient's heart, and applying said shock waveform therapy to the defibrillating electrodes of both the right atrial lead and the left ventricular lead simultaneously to terminate atrial fibrillation.

10 40. The method of claim 34, including the steps of detecting the local ECG at the left and right ventricles, and comparing the characteristics of size and morphology thereof for diagnosis of cardiac activity from which to discriminate ventricular and supraventricular tachycardias from one another.

15 41. The method of claim 39, including the step of selecting leads to be implanted in the right atrium, right ventricle, and left ventricle of the patient's heart which are covered with an insulating sheath selected from a group comprising silicone and polyurethane, and in which the sheath is coated with a material selected from a group comprising iridium oxide and titanium nitrate.

20 42. The method of claim 29, including the steps of implanting separate electrical leads each with a pacing electrode thereon in the right and left atria of the patient's heart, and simultaneously pacing both atria.

25 43. The method of claim 33, including the steps of administering a platelet inhibitor into the patient's vascular system for a limited period of time to facilitate healing and a build-up of connective tissue on electrodes of the lead implanted in the left ventricle to avoid interference with operation of the aortic valve.

30 44. A method for providing therapy to a patient from an implanted medical interventional device to treat cardiac dysrhythmias, comprising the steps of simultaneously stimulating the right and left ventricles of the patient's heart

when ventricular pacing is found to be needed, for enhancing hemodynamics, and defibrillating the heart by applying electrical defibrillation shocks to a point in the left ventricle when ventricular defibrillation is detected.




FIG. 1




FIG. 2




FIG. 3





FIG. 4



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61N 1/368, 1/39, 1/05	A3	(11) International Publication Number: WO 00/04950 (43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: PCT/US99/16656 (22) International Filing Date: 23 July 1999 (23.07.99) (30) Priority Data: 09/121,523 23 July 1998 (23.07.98) US (71) Applicant: INTERMEDICS INC. [US/US]; 4000 Technology Drive, Angleton, TX 77515 (US). (71)(72) Applicants and Inventors: ALT, Eckhard [DE/DE]; Eichendorff Strasse 52, D-85521 Ottobrunn (DE). SANDERS, Richard [US/US]; 14122 Lofty Mountain Trail, Houston, TX 77062 (US). STOTTS, Lawrence, J. [US/US]; 327 Linden Lane, Lake Jackson, TX 77566 (US). (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published [With international search report. (88) Date of publication of the international search report: 4 May 2000 (04.05.00)	

(54) Title: METHOD AND APPARATUS FOR DUAL CHAMBER BI-VENTRICULAR PACING AND DEFIBRILLATION



(57) Abstract

Device and method are disclosed in which leads with pacing and defibrillating electrodes are implanted into both the right and left ventricles of a patient's heart to enable simultaneous pacing of both ventricles to reduce the width of the QRS complex of the patient's cardiac activity to a more normal duration, and, when appropriate, to apply electrical shock waveforms to both ventricles simultaneously for lower energy defibrillation of the ventricles. In applying the defibrillation therapy, the defibrillating electrode in the left ventricle may be used as the anode and the defibrillating electrode in the right ventricle may be used as the cathode, or both ventricular defibrillating electrodes may be the anode and the metal case in which the shock waveform generator is implanted may be the cathode. Implanting a lead with pacing and defibrillating electrodes in the right atrium enables selective pacing and defibrillation of the atria, in which atrial fibrillation is treated by applying the shock waveform across the right atrial and left ventricular defibrillation electrodes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International application No
PCT/US 99/16656

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61N1/368 A61N1/39 A61N1/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 928 688 A (MOWER MORTON M) 29 May 1990 (1990-05-29)	1, 13
Y	column 5, line 16-49	2, 3
A	---	14, 26-28
X	US 5 540 727 A (SALO RODNEY W ET AL) 30 July 1996 (1996-07-30)	13, 14
A	column 3, line 20-42	1, 26-28
E	WO 99 44682 A (MOWER MORTON M) 10 September 1999 (1999-09-10)	15, 16
A	page 5, line 9-21	1, 9-13, 17, 18, 26, 28
	page 7, line 16-18	

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 February 2000

Date of mailing of the international search report

01 03 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Grossmann, C.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/16656

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 784 994 A (PACESETTER AB) 23 July 1997 (1997-07-23)	2,3
A	the whole document	4
A	EP 0 601 804 A (SMITH & NEPHEW RICHARDS INC) 15 June 1994 (1994-06-15) page 3, line 36-39 page 11, line 56 -page 12, line 33	2-4,7,8
A	US 5 050 601 A (KUPERSMITH JOEL ET AL) 24 September 1991 (1991-09-24) column 2, line 41-51	1,9-11, 13, 15-18, 26-28
A	US 5 224 475 A (BERG GARY L ET AL) 6 July 1993 (1993-07-06) column 2, line 27-41 column 3, line 34-51	1,9-11, 13, 15-18, 26-28
A	US 5 720 768 A (VERBOVEN-NELISSEN YVES) 24 February 1998 (1998-02-24) column 5, line 23-59; figures 5A,5B	1,13,14, 26-28
A	US 5 324 324 A (VACHON DAVID J ET AL) 28 June 1994 (1994-06-28) column 3, line 27-42 column 4, line 26 -column 5, line 20	2-4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/16656

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19-25, 29-44
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,9-18,26-28

Implantable pulse generator for simultaneous application of a treatment pulse or shock in both ventricles.

2. Claims: 2-8

Lead with low thrombogenicity.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/16656

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4928688	A	29-05-1990	NONE	
US 5540727	A	30-07-1996	NONE	
WO 9944682	A	10-09-1999	AU 2981499 A	20-09-1999
EP 0784994	A	23-07-1997	JP 9192239 A	29-07-1997
EP 0601804	A	15-06-1994	US 5509933 A	23-04-1996
			US 5477864 A	26-12-1995
			AU 5219693 A	16-06-1994
			JP 6233811 A	23-08-1995
			US 5573401 A	12-11-1996
			US 5545227 A	13-08-1996
			US 5690670 A	25-11-1997
			US 5782910 A	21-07-1998
			US 5716400 A	10-02-1998
			US 5676632 A	14-10-1997
			US 5562730 A	08-10-1996
			US 5713947 A	03-02-1998
			US 5685306 A	11-11-1997
			US 5674280 A	07-10-1997
			US 5683442 A	04-11-1997
			CA 2110779 A	08-06-1994
US 5050601	A	24-09-1991	NONE	
US 5224475	A	06-07-1993	AU 660518 B	29-06-1995
			AU 3059492 A	15-06-1993
			CA 2121795 A	27-05-1993
			EP 0618823 A	12-10-1994
			JP 6510688 T	01-12-1994
			US 5344430 A	06-09-1994
			WO 9309844 A	27-05-1993
US 5720768	A	24-02-1998	CA 2248952 A	27-11-1997
			EP 0901397 A	17-03-1999
			WO 9744090 A	27-11-1997
US 5324324	A	28-06-1994	NONE	

Form PCT/ISA/210 (patent family annex) (July 1992)